Entrectinib is a central nervous system (CNS)‐active potent inhibitor of TRKA/B/C and ROS1 [17, 18, 19] approved for the treatment of adult and paediatric patients aged ≥12 years with NTRK fusion‐positive (NTRK‐fp) solid tumours and adults with ROS1 fusion‐positive (ROS1‐fp) NSCLC. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.